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Abstract
Introduction The administration of prophylactic antibiotics via
the respiratory tract is one of several strategies for the
prevention of intensive care unit (ICU)-acquired pneumonia. We
systematically examined the available evidence regarding the
effect of prophylactic antibiotics administered via the respiratory
tract on the development of ICU-acquired pneumonia, mortality,
colonization of the respiratory tract, emergence of antimicrobial
resistance, and toxicity.
Methods We searched the PubMed database (January 1950 to
September 2005) and references from relevant articles to
identify trials that provided comparative data regarding the
above-mentioned outcomes. Two investigators independently
performed the data extraction to calculate the effect of the
studied intervention on clinically relevant outcomes.
Results Our meta-analysis includes 8 comparative trials (5
randomized controlled trials (RCTs) and 3 non-randomized
trials) studying gentamicin (3 trials), polymyxins (3 trials),
tobramycin (1 trial), and ceftazidime (1 trial) that studied 1,877
patients. Our primary analysis, which included the 5 RCTs,
revealed that ICU-acquired pneumonia was less common in the
group of patients that received the antibiotic prophylaxis (odds
ratio (OR) = 0.49, 95% confidence interval (CI) 0.32–0.76). No
difference in mortality was found between the compared groups
(OR = 0.86, 95% CI 0.55–1.32). Data were too limited to
p e r m i t  a n  a n a l y s i s  o f  c o l o n i z a t i o n  w i t h  Pseudomonas
aeruginosa. A secondary analysis, adding the three non-
randomized comparative trials, did not reveal substantially
different results regarding ICU-acquired pneumonia and
mortality, while fewer patients were colonized with P.
aeruginosa in the group that received prophylaxis, compared to
the group of patients that received no prophylaxis (OR = 0.51,
95% CI 0.30–0.86). No serious drug-related toxicity was noted.
No meaningful systematic analysis of the evidence regarding the
emergence of resistance could be performed in the studies
included in our meta-analysis.
Conclusion The limited available evidence supports that
prophylactic administration of antibiotics via the respiratory tract
is associated with reduction of occurrence of ICU-acquired
pneumonia. However, there is evidence from non-comparative
studies that this preventive strategy may lead to an increase in
the emergence of resistant bacteria. Thus, further investigation,
at least in ICU patients at high risk for development of ICU-
acquired pneumonia, is warranted, including a more systematic
evaluation of issues related to the emergence of resistance.
Introduction
Intensive care unit (ICU)-acquired infection of the respiratory
tract is a common complication among patients who receive
medical care in this setting. Colonization of the respiratory
tract by Gram-negative and Gram-positive bacteria may pre-
cede infection of the lower respiratory tract, including pneu-
monia, that is associated with considerable morbidity and
mortality. There have been several efforts to reduce the devel-
opment of ICU-acquired pneumonia using various strategies,
including selective bowel decontamination, that have been
summarized recently [1,2]. Among them are studies examining
the effectiveness of administration of antimicrobial agents via
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the respiratory tract in the prevention of bacterial colonization
of the respiratory tract and ICU-acquired pneumonia.
Recommendations from the Centers for Disease Control and
Prevention strongly discourage the administration of antibiot-
ics via the respiratory tract for the prevention of ICU-acquired
pneumonia [3,4]. In addition, the Canadian Critical Care Trials
Group and the Canadian Critical Care Society also discour-
age such a strategy in the published clinical guidelines regard-
ing the evidence-based clinical practice for the prevention of
ventilator-associated pneumonia [1]. We sought to systemati-
cally examine the evidence related to the above guidelines by
performing a meta-analysis of comparative trials studying the
effect of the administration of antibiotics via the respiratory
tract on the colonization of the respiratory tract by bacteria and
development of ICU-acquired pneumonia.
Methods
Data sources
Two investigators (IIS and IAB) independently performed the
literature search, study selection, and data extraction. Discrep-
ancies between these two investigators were resolved in
meetings of all authors. The relevant comparative trials for this
meta-analysis were identified from searches of PubMed (Janu-
ary 1950 to September 2005) and references from relevant
articles. The key terms that we used for the literature search
were aerosolised, nebulised, nebulized, endotracheal, intratra-
cheal, micronebulised, micronebulized, nosocomial pneumo-
nia, ventilator-associated pneumonia, and ICU-acquired
pneumonia. Abstracts presented in international conferences
were not searched.
Study selection
A comparative trial was considered eligible for inclusion in our
meta-analysis if it compared the effectiveness of an antibiotic
administered via the respiratory tract with placebo or no drug
on the colonization of the respiratory tract, ICU-acquired pneu-
monia, and/or mortality. Both randomized controlled trials
(RCTs) and non-randomized comparative trials were allowed
to be included in our meta-analysis. Articles written in any lan-
guage were allowed to be included in our meta-analysis.
Data extraction
The data extracted from the articles for further analysis were
the study population, the dosage and the duration of the
administered drugs, the number of clinically evaluable
patients, ICU-acquired pneumonia, colonization of the respira-
tory tract by various micro-organisms, mortality, emergence of
resistance, and toxicity. A quality review of each RCT was per-
formed by examining details of randomization, generation of
random numbers, details of double-blinding procedure, infor-
mation on withdrawals, and concealment of allocation [5]. One
point was awarded for the specification of each of the above
criteria; the maximum score for a study is 5. High quality RCTs
score more than 2 points, while low quality RCTs score 2 or
fewer points, according to the reported methodology.
Definition of outcomes
The occurrence of pneumonia during the ICU stay and all
cause and pneumonia-related mortality were considered the
primary outcome measures of this meta-analysis. In addition,
colonization with Pseudomonas aeruginosa, any reported tox-
icity, and emergence of resistance were considered second-
ary outcomes of analysis. Pneumonia was defined by clinical,
laboratory, and/or imaging findings attributed by the authors of
the trials to this infection. However, if the cases of pneumonia
were reported separately into possible, probable, or definitive
(documented), only the last two categories were included in
our analysis. Colonization was defined by the isolation of one
or more micro-organisms from sputum, bronchial secretions,
or bronchoalveolar lavage specimens of the patients without
accompanying evidence of infection of the respiratory tract.
Any toxicity or emergence of antimicrobial resistance reported
by the authors of the included studies was evaluated and ana-
lyzed when possible.
We performed a primary analysis of outcomes by including
only RCTs. In addition, we performed secondary analyses by
including all trials (both RCTs and non-randomized compara-
tive trials), as well as by examining outcomes in subsets of
patients, namely, intubated patients, patients treated with pol-
ymyxins, patients that received prophylactic antibiotics in aer-
osolized form, and patients in whom prophylactic antibiotics
were instilled endotracheally.
Data analysis and statistical methods
Statistical analyses were performed using the 'Meta-analyst'
software (Joseph Lau, Tufts University School of Medicine,
Boston, MA, USA) and the S-Plus 6.1 statistical software
(Insightful Corp., Seattle, WA, USA). Pooled odds ratios
(ORs) and 95% confidence intervals (CI) for all primary and
secondary outcomes were calculated by using both the Man-
tel-Haenszel fixed effects and the DerSimonian-Laird random
effects models [6-8]. The heterogeneity between studies was
assessed by using the chi-square test; a p value lower than
0.10 was defined to note statistical significance in the analysis
of heterogeneity. For all analyses, results from the fixed effects
model are presented only when there was no heterogeneity
between studies; otherwise results from the random effects
model are presented. The reported outcome rates of the ana-
lyzed studies were weighted by the inverse of their variance
with the fixed effects model. Small studies bias was assessed
by the funnel plot method using the Egger's test [9].
Results
Study selection
In Figure 1 we present the steps we followed in order to select
the relevant studies for our analysis. As shown, we identified
311 studies from the search of the PubMed database, as wellAvailable online http://ccforum.com/content/10/4/R123
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as from the reading of the references of relevant studies. From
these, we identified 12 studies that examined the use of pro-
phylactic antibiotics administered via the respiratory tract for
the prevention of ICU-acquired pneumonia [10-21]. Finally,
eight studies (five RCTs plus three non-randomized prospec-
tive trials) that compared the administration of prophylactic
antibiotics via the respiratory tract with the administration of
placebo (five studies) or no drug (three studies) fulfilled our
Figure 1
Flow diagram of reviewed articles Flow diagram of reviewed articles.Critical Care    Vol 10 No 4    Falagas et al.
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inclusion criteria and were further analyzed (Table 1)
[11,13,15,17-21]. The eight studies encompassed a total of
1,877 patients.
The quality assessment of the five RCTs included in our study
(evaluating the presence of randomization and blinding, their
appropriateness, and the presence of information on with-
drawals) showed that the quality of two RCTs was high
[13,21], while the quality of the other three was low (equal to
or less than two points) [11,17,18]. The mean quality score of
the included RCTs was 2.6 (in a 0 to 5 scale), which is con-
sidered good.
Drug administration
In Table 1 we present various characteristics of the trials
included in our analysis. In four of the analyzed studies the anti-
biotic prophylaxis was given in the form of aerosolized prepa-
rations [11,15,18,21] whereas antibiotics were administered
with endotracheal instillation to patients in the rest of the stud-
ies [13,17,19,20]. The drugs used were gentamicin (three
studies) [13,17,20], polymyxins (three studies; specifically,
polymyxin B in two studies [11,15] and colistin in one study
[19]), tobramycin (one study) [18], and ceftazidime (one
study) [21]. The duration of therapy was one week in one
study, two weeks in two studies, until the time of extubation in
Table 1
Characteristics of comparative trials included in the meta-analysis
Reference Year Type of trial Study quality 
score
Study 
population/
setting
Method for 
the micro-
biological 
diagnosis of 
pneumonia
Length of 
ICU stay 
(days)
Duration of 
mechanical 
ventilation 
(days)
Studied 
drug/
dosage
Drug 
administration
Mode of 
administration
ITT No. of 
patients 
clinically 
evaluable
Wood et al. 
[21]
2002 Double-blind, 
placebo-
controlled 
RCT
5 Mechanically 
ventilated for 
>2 days, 
trauma patients 
with >1 risk 
factor for post-
traumatic 
pneumonia; 
ICU; USA
Bronchoalv
eolar lavage
19 ± 11 vs 
21 ± 12
16 ± 11 vs 
18 ± 13
Ceftazidime
: 250 mg 
every 12 
hours
For 7 days Aerosolized 59 20 vs 20
Rouby et al. 
[19]
1994 Non-
randomized 
clinical trial
NA Mechanically 
ventilated for 
>3 days; 
surgical ICU; 
France
Bronchoalv
eolar lavage
No data Survivors: 
18 ± 12 vs 
12 ± 14 
Non-
survivors: 9 
± 5 vs 8 ± 
4
Colistin: 
200,000 
units every 
3 h
For 2 weeks Endotracheal 
instillation
598 347 vs 
251
Rathgeber 
et al. [18]
1993 RCT 2 Mechanically 
ventilated; ICU; 
Germany
Bronchial 
secretions
No data 17 vs 13 Tobramycin: 
80 mg 
every 6 
hours
Until the time 
of extubation
Aerosolized 69 29 vs 40
Lode et al. 
[17]
1992 Double-blind, 
placebo-
controlled, 
RCT
2 Mechanically 
ventilated for 
>3 days; 5 
European ICUs
No data No data No data Gentamicin: 
40 mg 
every 6 
hours
Until the time 
of extubation 
(<14 days)
Endotracheal 
instillation
199 85 vs 77
Vogel et al. 
[20]
1981 Non-
randomized, 
controlled 
clinical trial
NA Mechanically 
ventilated for 
>5 days; 
medical ICU; 
Germany
Tracheal 
aspirates
No data 8.3 vs 7.4 Gentamicin: 
40 mg 
every 6 
hours
For 2 weeks Endotracheal 
instillation
40 20 vs 20
Klick et al. 
[15]
1975 Double-blind, 
placebo-
controlled, 
non-
randomized 
clinical trial
NA Mechanically 
ventilated or 
not; 
respiratory-
surgical ICU; 
USA
Sputum; 
Tracheal 
aspirates
5.1 vs 5.3 No data Polymyxin 
B: 2.5 mg/
kg body 
weight/day 
in 6 divided 
doses
Throughout 
the entire ICU 
stay
Aerosolized 744 355 vs 
337
Klatersky et 
al. [13]
1974 Placebo-
controlled 
RCT
3 Tracheostomis
ed 
neurosurgical 
ICU; Belgium
Sputum; 
tracheal 
aspirates; 
bronchial 
secretions
19.9 vs 
14.7
NA Gentamicin: 
80 mg 
every 8 
hours
Throughout 
the entire ICU 
stay
Endotracheal 
instillation
110 43 vs 42
Greenfield 
et al. [11]
1973 RCT 1 Mechanically 
ventilated or 
not, high-risk 
patients; 
respiratory-
surgical ICU; 
USA
Sputum 9.0 (median 
6.0) vs 7.6 
(median 
6.0)
No data Polymyxin 
B: 2.5 mg/
kg body 
weight/day 
in 6 divided 
doses
Throughout 
the entire ICU 
stay
Aerosolized 58 33 vs 25
Values are for the group receiving prophylactic antibiotics by the respiratory tract versus (vs) the control group. ICU, intensive care unit; ITT, 
intention-to-treat; NA, non applicable; RCT, randomized controlled trial.Available online http://ccforum.com/content/10/4/R123
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two studies, and throughout the entire ICU stay of patients in
the three remaining studies.
Only two of the trials included in our analysis provided data
regarding the pulmonary drug concentrations of the drugs
administered via the respiratory tract. In the first trial [21], in
which ceftazidime was administered by aerosol, ceftazidime
concentrations were detectable by bronchoalveolar lavage
procedures in 16 of 19 ceftazidime-recipients; 3 of these 16
patients had concentrations below the breakpoint for ceftazi-
dime sensitivity. In the second trial gentamicin was instilled
endotracheally, the mean level of which in bronchial secretions
was 230 µg/ml ± 72 µg/ml. Thus, the scarcity of relevant data
did not allow us to validate the effectiveness of the various
modes of administration via the respiratory tract [13].
Data regarding the administration of systemic antibiotics dur-
ing the administration of prophylactic antibiotics via the respi-
ratory tract was reported in five of the analyzed studies;
however, no pooling of data could be performed since there
was considerable heterogeneity [11,13,15,18,21]. Specifi-
cally, Klastersky and colleagues [13] reported that systemic
antibiotics were given more frequently (p < 0.01) to the
patients in the placebo-treated group than those who were
treated with gentamicin endotracheally. In the study by Rath-
geber and colleagues [18], it is mentioned that the subgroup
of patients with multiple traumas received systemic prophy-
laxis with metronidazole and cefuroxime, regardless of their
randomization to receive prophylaxis or not via the respiratory
tract. Greenfield and colleagues [11] reported that 88% of the
polymyxin-treated patients and 76% of the patients in the pla-
cebo group received antibiotics systemically during their ICU
stay (which was also the time during which they received aer-
osolized polymyxin B or placebo). Similarly, in the study by
Klick and colleagues [15], 53% of the polymyxin-treated
patients and 49% of the patients in the placebo group
received antibiotics systemically. Finally, in the study by Wood
and colleagues [21], only data regarding patients that devel-
oped pneumonia were presented; systemic antibiotics had
been administered in 6/6 patients in the ceftazidime group and
11/13 in the control group, a result without statistical
significance.
Mortality
In Table 2 we present data regarding the outcomes of our
analysis. All cause mortality during the ICU stay was reported
in all five included RCTs (Table 2) [11,13,17,18,21]. No
difference in mortality between prophylactic antibiotic therapy
Table 2
Outcome data from the selected comparative trials for the meta-analysis
Reference Year ICU-acquired 
pneumonia (time of 
evaluation)
Mortality due to 
pneumonia (time of 
evaluation)
All cause mortality 
(time of evaluation)
Proportion of 
patients with 
colonization of 
respiratory tract by 
P. aeruginosa
Emergence of 
resistance
Toxicity
Wood et al. [21] 2002 3/20 (15%) vs 11/
20 (55%) (day 14); 
6/20 (30%) vs 13/
20 (65%) (entire 
ICU stay)
NA 3/20 (15%) vs 6/20 
(30%) (entire ICU 
stay)
No data No clinically 
significant changes 
in bacterial 
sensitivity patternsa
None
Rouby et al. [19] 1994 97/347 (28%) vs 
100/251 (40%) 
(week 2)
NA 42/347 (12%) vs 
31/251 (12%) 
(week 2)
No data Not observeda Not mentioned
Rathgeber et al. [18] 1993 5/29 (17%) vs 17/
40 (43%) (entire 
ICU stay)
2/29 (7%) vs 4/40 
(10%) (entire ICU 
stay)
4/29 (14%) vs 8/40 
(20%) (entire ICU 
stay)
2/171 (1%) vs 44/
215 (20%)b
Non-significantly 
higher incidence 
mainly of S. 
epidermidisa
None
Lode et al. [17] 1992 29/85 (34%) vs 25/
77 (32%) (day 16)
NA 23/85 (27%) vs 25/
77 (39%) (week 4)
2/85 (2%) vs 6/77 
(8%)
No data Not mentioned
Vogel et al. [20] 1981 Less frequent in the 
gentamicin group
NA No data 5/20 (25%) vs 9/20 
(45%)
No evidence of 
increasea
Not mentioned
Klick et al. [15] 1975 16/355 (5%) vs 24/
337 (7%) (entire 
ICU stay)
5/374 (1%) vs 2/
370 (0.5%) (entire 
ICU stay)
45/374 (12%) vs 
45/370 (12%) 
(entire ICU stay)
6/374 (2%) vs 36/
370 (10%)
Did not occur to any 
significant extenta
Not mentioned
Klastersky et al. [13] 1974 5/43 (12%) vs 17/
42 (40%) (entire 
ICU stay)
2/43 (5%) vs 4/42 
(10%) (entire ICU 
stay)
23/43 (54%) vs 16/
42 (38%) (entire 
ICU stay)
39/228 (17%) vs 
32/174 (18%)b
The isolated 
microorganisms from 
the drug group were 
slightly more 
resistant to 
gentamicina
Not mentioned
Greenfield et al. [11] 1973 2/33 (6%) vs 4/25 
(16%) (entire ICU 
stay)
NA 4/33 (12%) vs 6/25 
(24%) (entire ICU 
stay)
0/33 (0%) vs 3/25 
(12%)
Not encountered 
frequently (only six 
Gram-negative 
bacteria resistant to 
polymyxin)a
Negligiblea
Values are for the group receiving prophylactic antibiotics by the respiratory tract versus (vs) the control group. aAccording to the investigators of 
the study. bRefers to proportion of isolates. ICU, intensive care unit;Critical Care    Vol 10 No 4    Falagas et al.
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administered via the respiratory tract and no therapy or pla-
cebo therapy was found (all cause mortality; OR = 0.86, 95%
CI 0.55–1.32, fixed effects model; Figure 2a).
Pneumonia-related mortality was reported in two RCTs (Table
2) [13,18]. In each of these RCTs no difference in pneumonia-
related mortality was found between patients in the prophylac-
tic antibiotic therapy group and in the control group (pneumo-
nia-related mortality: 1st RCT [13], 2/43 (5%) versus 4/42
(10%), p = 0.4; 2nd RCT [18], 2/29 (7%) versus 4/40 (10%),
p = 0.99).
ICU-acquired pneumonia
Pneumonia occurred less frequently in the prophylaxis arm
compared to the no-prophylaxis arm, a statistically significant
result (ICU-acquired pneumonia: OR = 0.49, 95% CI 0.32–
0.76, fixed effects model, 5 RCTs; Figure 3a)
[11,13,17,18,21].
Colonization with P. aeruginosa
Four RCTs reported specific data regarding the colonization of
the respiratory tract by P. aeruginosa [11,13,17,18]. However,
two of them reported only the proportion of P. aeruginosa iso-
Figure 2
Odds ratios of mortality between patients who received antibiotic prophylaxis via the respiratory tract and those who received placebo or no therapy Odds ratios of mortality between patients who received antibiotic prophylaxis via the respiratory tract and those who received placebo or no therapy. 
(a) Primary analysis (only randomized controlled trials); (b) secondary analysis (including non-randomized trials). Vertical line = 'no difference' point 
in mortality between the two regimens. Horizontal lines = 95% confidence interval. Square = odds ratio; the size of each square denotes the propor-
tion of information given by each trial. Diamond/triangle = pooled odds ratio for all studies.
Figure 3
Odds ratios of intensive care unit-acquired pneumonia between patients who received antibiotic prophylaxis via the respiratory tract and those who  received placebo or no therapy Odds ratios of intensive care unit-acquired pneumonia between patients who received antibiotic prophylaxis via the respiratory tract and those who 
received placebo or no therapy. (a) Primary analysis (only randomized controlled trials); (b) secondary analysis (including non-randomized trials). 
Vertical line = 'no difference' point in intensive care unit-acquired pneumonia between the two regimens. Horizontal lines = 95% confidence interval. 
Square = odds ratio; the size of each square denotes the proportion of information given by each trial. Diamond/triangle = pooled odds ratio for all 
studies.Available online http://ccforum.com/content/10/4/R123
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lates among all isolated organisms without specifically refer-
ring to the number of patients from whom these organisms
were isolated [13,18]. Thus, data from the remaining two
RCTs [11,17] were not enough to permit a meta-analysis of
colonization with P. aeruginosa. In each of these RCTs
[11,17] a similar proportion of patients was colonized with P.
aeruginosa in the group that received prophylaxis, compared
to the group of patients that received no prophylaxis
(colonization with P. aeruginosa: 1st RCT [11], 0/33 (0%) ver-
sus 3/25 (12%), p = 0.07; 2nd RCT [18], 2/85 (2%) versus
6/77 (8%), p = 0.15).
Emergence of resistance
Data regarding the number and type of the isolated organisms
were reported in six of the studies (three RCTs [13,18,21])
included in our analysis [13,15,17,18,20,21]. However, there
was limited information regarding the in vitro antimicrobial sus-
ceptibility of the isolated pathogens. Specifically, data regard-
ing bacteria resistant to gentamicin, polymyxins, and
ceftazidime were reported in one [13], three [11,15,19] and
one [21] study, respectively. Unfortunately, no systematic
analysis of the emergence of resistance could be performed in
the studies included in our meta-analysis to allow a meaningful
synthesis of evidence regarding this important outcome. In
Table 2 we present the information regarding the emergence
of resistance reported in the analyzed studies, if any.
Toxicity
In five of the included studies no data regarding toxicity were
reported. In two RCTs it was reported that no toxicity was
observed during the trials [18,21], whereas in the remaining
RCT the authors characterized the observed toxicity negligible
[11], without reporting any further detail (Table 2).
Secondary analyses
The ICU-acquired pneumonia, all cause mortality, pneumonia-
related mortality, and colonization with P. aeruginosa were
analyzed by also including the three non-randomized compar-
ative trials [15,19,20]: pneumonia, OR = 0.50, 95% CI 0.33–
0.76, data from 7 studies [11,13,15,17-19,21] (Figure 3b);
mortality, OR = 0.93, 95% CI 0.72–1.22, data from 7 studies
[11,13,15,17-19,21] (Figure 2b); pneumonia-related mortal-
ity, OR = 0.98, 95% CI 0.39–2.49, fixed effects model, data
from 3 studies; colonization with P. aeruginosa, OR = 0.51,
95% CI 0.30–0.86, data from 4 studies [11,15,17,20]. Of
note, the study by Klick and colleagues [15] was terminated
prematurely because of an increase in colonization and infec-
tion by P. aeruginosa in the group without prophylaxis, which
forced the physicians to use prophylaxis with aerosolized
polymyxin for all patients due to the good results that were
observed with this mode of treatment in their unit [15].
In addition, ICU-acquired pneumonia and all cause mortality
were analyzed in four subsets of patients. The 1st subset com-
prised studies that included only intubated patients (pneumo-
nia, OR = 0.60, 95% CI 0.45–0.80; and mortality, OR = 0.83,
95% CI 0.58–1.21; 4 studies analyzed for both outcomes [17-
19,21]); these studies also represented the subset of the most
recent studies, published after 1990. The 2nd subset com-
prised studies that examined polymyxins as antibiotic prophy-
laxis (pneumonia, OR = 0.58, 95% CI 0.43–0.79; mortality,
OR = 0.94, 95% CI 0.68–1.30; 3 studies analyzed for both
outcomes [11,15,19]). The 3rd subset comprised studies in
which aerosolized prophylactic antibiotics were administered
(pneumonia, OR = 0.44, 95% CI 0.27–0.72; mortality, OR =
0.84, 95% CI 0.57–1.24; 4 studies analyzed for both out-
comes [11,15,18,21]). The 4th subset comprised studies in
which prophylactic antibiotics were instilled endotracheally
(pneumonia, OR = 0.61, 95% CI 0.45–0.81; mortality, OR =
1.04, 95% CI 0.68–1.59; 3 studies analyzed for both out-
comes [13,17,19]).
Discussion
The main finding of our study is that development of ICU-
acquired pneumonia is less common in patients who received
prophylactic antibiotics via the respiratory tract compared to
placebo or no drug. Specifically, the OR for development of
ICU-acquired pneumonia was 0.50 for patients who received
antibiotic prophylaxis via the respiratory tract compared to
those who received no prophylaxis. No difference in mortality
was found between patients in the two compared groups.
Data from RCTs were not enough to permit an analysis of col-
onization with P. aeruginosa. Nevertheless, in a secondary
analysis that also included the three non-randomized trials, col-
onization with P. aeruginosa was found to be less in the group
of patients that received prophylaxis. To our knowledge, this is
the first meta-analysis that has examined the effectiveness of
prophylactic antibiotics administered via the respiratory tract
against the development of ICU-acquired pneumonia.
Some data from animal and laboratory studies support the pro-
phylactic use of antibiotics administered locally in the respira-
tory tract [22-24]. Animal studies have provided supporting
data for the local administration of antibiotics for the preven-
tion of development of colonization and infection of the respi-
ratory tract. Specifically, prevention of colonization of the
respiratory tract by highly invasive micro-organisms was
shown after the prophylactic administration of topical instilla-
tion of polymyxin B into the respiratory tract in 13 consecutive
studied baboons [22].
In addition, pharmacokinetic studies showed that the concen-
tration in the endobronchial fluid of antibiotics administered via
the respiratory tract is high. Specifically, in a comparative
study of the administration of 2 mg/kg of body weight of gen-
tamicin via the intramuscular route or the respiratory tract
showed that, after systemic administration, the serum concen-
tration of gentamicin was more than 6 µg/ml and the endo-
bronchial less than 2 µg/ml, while the respective values after
endotracheal instillation of the antibiotic were 1 µg/ml and 400Critical Care    Vol 10 No 4    Falagas et al.
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µg/ml [24]. In another study of lung distribution bronchokinet-
ics of aerosolized tobramycin, the mean lung tissue concentra-
tions of tobramycin were 5.5 and 3.61 µg/ml 4 and 12 hours
after nebulization, respectively [23]. It should be emphasized
that the effect of the specific way of administration of antibiot-
ics via the respiratory tract on the concentrations accom-
plished in the endobronchial fluid or the lung parenchyma has
not been systematically examined. For example, Wood and
colleagues [25] reported that the amount of the nebulized
dose that reaches the distal airways of the lungs may be sev-
eral times higher with the use of an appropriate nebulizer, ven-
tilator and administration technique compared to non-
standardized ways of administration of antibiotics into the res-
piratory tract.
In addition to patients who receive care in the ICU setting,
patients susceptible to colonization of the respiratory tract by
various bacteria and, subsequently, the development of lower
respiratory tract infections are those with underlying lung dis-
ease, including cystic fibrosis, bronchiectasis, and severe
chronic obstructive pulmonary diseases. The effect of the
administration of antibiotics via the respiratory tract on the pre-
vention of respiratory tract colonization and infection was also
investigated in these patient populations. It has been shown
that the bacteria most frequently isolated from the sputum of
patients with bronchiectasis are P. aeruginosa, Staphylococ-
cus aureus,  Haemophilus influenzae, and Streptococcus
pneumoniae. It has also been shown that an increase of P. aer-
uginosa local density in the respiratory tract may be associ-
ated with deterioration of lung function and increase of
morbidity and mortality of patients with cystic fibrosis. Only
three RCTs have examined the prophylactic effect of antibiot-
ics administered via the respiratory tract in patients with bron-
chiectasis [26-28]. In general, a reduction of the colonization
and infection of the respiratory tract was noted in these trials,
although concerns about possible development of antimicro-
bial resistance were also raised.
The Canadian Critical Care Trials Group and the Canadian
Critical Care Society [1] as well as the Centers for Disease
Control and Prevention [3,4] suggest the avoidance of the
prophylactic administration of antibiotics via the respiratory
tract because of concerns about development of resistant
pathogens as well as the toxicity related to the administered
agents, based mainly on data from non-comparative trials [29-
32]. For example, in an old non-comparative study, coloniza-
tion of the respiratory tract by bacteria resistant to polymyxins,
such as S. aureus, coagulase-negative staphylococci, Entero-
coccus spp., flavobacteria, Serratia spp., Proteus spp. as well
as Candida spp., was noted in a proportion of patients who
received prophylactic polymyxin B via the respiratory tract
[10]. Although the findings of that study indicated that the
administration of polymyxin via the respiratory tract for the pre-
vention of ICU pneumonia was not effective and was in fact
harmful because it was associated with toxicity and emer-
gence of resistance, no direct comparison was made in that
study with a group of patients that did not receive such a pre-
ventive therapy. Also, the authors of that study found an
increase in pneumonia-associated mortality during the use of
aerosolized polymyxin, compared to previous time periods in
the same center when no polymyxin via the respiratory tract
was used, a fact thought to be related to the emergence of the
aforementioned organisms. However, the authors did not per-
form statistical comparisons to evaluate this difference and it
should be emphasized that they compared patients from differ-
ent time periods.
The emergence of resistant strains after the use of inhaled pol-
ymyxins has also been reported in another non-comparative
study. In that study [33] an outbreak of nosocomial Flavobac-
terium meningosepticum respiratory infections was consid-
ered to be associated with prophylactic use of aerosolized
polymyxin B. Twenty isolates of F. meningosepticum were iso-
lated from nine patients during a two and a half month period.
In five of them the bacterium caused pneumonia, resulting in
two deaths. All isolates were ciprofloxacin-only susceptible. In
addition, in the study by Klastersky and colleagues [14], the
comparison of two prophylactic aerosolized regimens, namely
gentamicin and aminosidin-polymyxin B combination, showed
that the use of these regimens, and especially the first one,
was associated with the emergence of gentamicin-resistant
strains.
The limited available evidence from the eight comparative trials
that we analyzed does not directly support the concern for the
development of resistant pathogens, as it was reported in the
four aforementioned studies. A possible explanation for this is
that, in the included studies, and especially in the more recent
ones [18,19,21], the prophylactic antibiotics were adminis-
tered for shorter periods of time compared to the studies dis-
cussed above. Also, the emergence of resistant organisms in
the studies included in our meta-analysis, apart from being
rare, was not found to be associated with any form of morbidity
or with increased mortality. It should be emphasized that the
decrease in the proportion of patients that develop pneumonia
should also result in a substantial decrease in the overall use
of systemically administered antibiotics. This in turn may lead
to a decrease in the emergence of organisms with antimicro-
bial resistance. However, data regarding this issue from the
analyzed studies were too heterogeneous to make any mean-
ingful synthesis of them. In fact, as none of the studies
included in our meta-analysis looked systematically at emer-
gence of resistance, we cannot comment on whether or not
administration of topical antimicrobial agents is associated
with development of resistance.
It is noteworthy that no major toxicity of the antibiotics admin-
istered via the respiratory tract as prophylaxis was noted in any
of the patients included in the analyzed trials that reported rel-
evant data. However, it should also be noted that local adverseAvailable online http://ccforum.com/content/10/4/R123
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effects from the respiratory tract after the prophylactic or ther-
apeutic administration of antibiotics were reported in other
studies. Most of these, however, were related to minor or mod-
erate bronchospasm that was alleviated by the appropriate
bronchodilator treatment [34,35].
Our study has several limitations. First, we included trials per-
formed in different time periods; this fact has an effect on the
antimicrobial resistance pattern of the isolated pathogens in
different studies and methods of diagnosis of pneumonia. For
example, the very small proportion of methicillin-resistant sta-
phylococci isolated in most of the analyzed studies represents
a significant difference in comparison to the current situation
in most ICUs worldwide. Second, we included trials that exam-
ined different medications; however, we performed sensitivity
analysis for a specific class of antibiotics, namely polymyxins,
administered via the respiratory tract and we found that the
results regarding the positive effect of the prophylactic local
agents on the development of ICU-acquired pneumonia and
overall mortality were not different from those of the main anal-
ysis. Third, we analyzed data mainly from patients who were
receiving mechanical ventilation, although three studies
included a minority of patients who were receiving care at the
ICU setting but not mechanical ventilation. Again, sensitivity
analysis of the studies that included only patients with
mechanical ventilation did not reveal different results com-
pared to the main analyses regarding the primary outcomes of
analysis. Fourth, we included in our meta-analysis trials that
were performed on populations that had a different profile of
risk factors. Fifth, we analyzed only the effect of antibiotic
prophylaxis via the respiratory tract on colonization by P. aeru-
ginosa due to the unavailability of relevant data for other organ-
isms. Sixth, the change from a positive to a negative culture of
tracheobronchial secretion specimens with the administration
of topical antibiotics may be due to suppression of microbial
growth rather than true eradication of colonization. However,
even if this change is due to suppression of microbial growth,
it may be of value as it is associated with reduction of occur-
rence of negative outcomes [36].
Another limitation of our meta-analysis is that the effect of pro-
phylactic antibiotics administered via the respiratory tract on
the length of the ICU stay and the hospital stay was not sys-
tematically analyzed in the included trials. In addition, the stud-
ies that were included in our meta-analysis did not report any
data regarding the cost effectiveness of the administration of
antibiotics via the respiratory tract for the prevention of ICU-
acquired pneumonia. Furthermore, we should note that there
may be a placebo effect, that is, that the administration of pla-
cebo, which is usually a small amount of normal saline in an
aerosolized form, may have an effect on the colonization and,
subsequently, the infection of the respiratory tract [37]. Also,
currently recommended strategies for reduction of ICU pneu-
monia, such as ventilator circuit changes, closed suction sys-
tems, and semi-recumbent positioning, were not standardized
or not even practiced in many of the included studies. There-
fore, current administration of antibiotics via the respiratory
tract should be reevaluated in combination with such non-
pharmacological preventive strategies. Most important of all, it
cannot be overemphasized that no reduction in mortality was
found between the compared groups in our meta-analysis.
This is a noteworthy result that could be due to a sample size
effect or, alternatively, due to lack of an effect of the adminis-
tered preventive measure on mortality. However, even without
a mortality benefit, the reduction of incidence of ICU-acquired
pneumonia is associated with a reduction of length of ICU stay
and costs.
Conclusion
Despite the above limitations, we think that our study offers
potentially useful data that may be of value to clinicians taking
care of patients in the ICU setting. The relevant evidence from
the available comparative trials shows that prophylactic admin-
istration of antibiotics via the respiratory tract in patients in the
ICU setting is associated with reduction of occurrence of ICU-
acquired pneumonia. However, it should be emphasized that
evidence from non-comparative studies supports that this pre-
ventive strategy may lead to an increase in the emergence of
resistant bacteria. We believe that the available evidence sug-
gests that further investigation and consideration of this pre-
ventive strategy, including a more systematic evaluation of
issues related to the emergence of resistance, is warranted, at
least for ICU patients at high risk for development of ICU-
acquired pneumonia.
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Key messages
•  There is limited evidence regarding the role of adminis-
tration of antimicrobial agents via the respiratory tract 
for the prevention of ICU-acquired pneumonia.
•  Data from five RCTs included in our meta-analysis sug-
gest that ICU-acquired pneumonia was less common in 
the group of patients that received antibiotic prophylaxis 
via the respiratory tract compared with those who 
received placebo or no therapy.
•  No difference in mortality was found between the com-
pared groups.
•  Although there is evidence from non-comparative stud-
ies that this preventive strategy may lead to an increase 
in the emergence of resistant bacteria, data from the 
comparative trials included in our analysis do not allow 
us to comment on whether or not administration of topi-
cal antimicrobial agents in the respiratory tract is asso-
ciated with the development of resistance.Critical Care    Vol 10 No 4    Falagas et al.
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